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Introduction

Current Research

Methods

Ø Persistent hypotension in patients affected by circulatory
shock is a common barrier to discharge in the ICU. Even
after these patients have been otherwise stabilized, low-level
hypotension ensures that they remain in the ICU on IV
vasopressors.
Ø Midodrine, an oral α1-agonist, has shown promise as an
adjunct therapy to wean patients off IV vasopressors and
facilitate earlier discharge from the ICU.
Ø Although Midodrine has been shown to be effective in
weaning patients off IV vasopressors in the ICU, there is
very little data regarding its use post-ICU.

Ø A recent study done by Rizvi MS, Nei AM, Gajic O, Mara
KC, and Barreto EF at the Mayo Clinic ICU, Rochester
published some interesting findings regarding discharge on
Midodrine.
Ø Despite similar baseline severity of illness scores and
comorbidities, discharge from the ICU on Midodrine
was associated with a shorter ICU LOS and a decreased
risk of in-hospital mortality.
Ø Among the patients discharged from the ICU on
Midodrine, 50% were concomitantly started on some
form of medication to lower blood pressure while still
on Midodrine.
Ø Midodrine continuation at hospital discharge was
associated with an increased risk of mortality in the 1
year after discharge.

Ø In this retrospective chart review, data from ICU patients
with persistent hypotension treated with Midodrine, at the
University of New Mexico Hospital, will be analyzed.
Ø Records will be reviewed to obtain data regarding details of
Midodrine treatment and discontinuation
Ø Date started and ended
Ø Dosing
Ø Blood pressure during use
Ø Taper schedule
Ø Incidence of continuation upon discharge
Ø ICU length of stay
Ø ICU mortality on Midodrine
Ø Adverse events related to Midodrine use
Ø Incidence of patients discharged on Midodrine especially
if concurrently with anti-hypertensives
Ø Our study has received IRB approval by the University of
New Mexico.

Mechanism of Action
Ø α1-agonists, such as Midodrine, bind to α receptors on
vascular smooth muscle and induce smooth muscle
contraction and vasoconstriction
Ø Selective α1-agonists have been shown to increase blood
pressure and are useful in settings of hypotension or shock

Study Objectives
Ø Midodrine has shown clinical utility as an oral α1-agonist
able to increase blood pressure and wean patients off IV
vasopressors, ultimately facilitating earlier discharge from
the ICU.
Ø However, the effects of Midodrine on patients discharged
from the ICU is an area of active research and much is still
unknown.
Ø This study will seek to determine:
Ø The indications for continuation of Midodrine upon ICU
discharge
Ø The methods physicians are currently employing to taper
or discontinue Midodrine outside of the ICU
Ø The frequency at which patients are being discharged on
Midodrine
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Future Plans
Ø Currently, we are in the process of reviewing charts to gather
data regarding details of Midodrine treatment in ICU
patients at the University of New Mexico.
Ø Once an adequate amount of data is collected, appropriate
statistical analyses will be run.
Ø Ultimately, the goal is to publish our findings as a guidance
to physicians considering discharging a patient on
Midodrine. The literature on this topic is sparse, and we
hope to assist physicians in making informed decisions
regarding the medication.
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